SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to recent pipeline expansion with the acquisition of VLX-1005 and ongoing advancements for its lead candidate, Tecarfarin, including a collaboration with Abbott for its pivotal Phase 3 trial. The community is sharply divided, with some investors highlighting Tecarfarin's market potential as a warfarin alternative and the stock's low float for significant upside, while others voice concerns over dilutive financing, cash burn, and allegations of widespread bot promotion.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is experiencing an explosive short squeeze, largely attributed to its low float and an AI-related deal. The community is actively comparing its parabolic surge to past runners like SMX, with many celebrating the squeeze and debating the sustainability of its extreme volatility and upward momentum.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

Glaxosmithkline plc - ADR

GSK is trending due to its significant acquisition of RAPT Therapeutics, bolstering its respiratory and immunology pipeline with a promising late-stage anti-IgE therapy. This strategic move, seen as a potential growth catalyst by the community, is drawing attention to the drug's novel quarterly dosing and its implications for expanding treatment options in allergy and inflammation, against a backdrop of ongoing pharmaceutical M&A activity.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending due to its announced record preliminary revenue and promising 2026 guidance, alongside the significant milestone of its Eversense 365 long-term CGM integrating with the twiist automated insulin delivery system. The community is actively discussing this breakthrough integration, which many view as a game-changer for its superior technology and improved market positioning, even as some express frustration with management's communication and slow commercialization pace. This puts the spotlight on SENS amidst broader competition and ongoing speculation about future partnerships.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is actively trending due to significant market discussion surrounding its ongoing multi-billion dollar acquisition strategy, exemplified by recent deals and persistent community speculation about future takeover targets. This M&A activity is concurrent with investor analysis of positive Phase 3 data for its eczema drug amlitelimab, alongside continued advancements and some regulatory challenges across its diverse pipeline, including in diabetes and vaccines.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup Co. is trending following its recent earnings report and subsequent analyst downgrades, which have ignited intense debate among investors. The community is actively discussing its potential as a defensive play and attractive dividend yield, alongside grappling with controversy surrounding an executive's alleged comments about product quality and 'bioengineered meat.'

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa (KAS) is experiencing intense community debate, driven by anticipation of smart contract implementation and potential Tier 1 exchange listings, alongside recent whale accumulation activities. Supporters are highly bullish, citing its unique BlockDAG Proof-of-Work technology as a scalable and secure solution for payments, while a vocal segment labels it a 'scam' or 'rugpull' due to past price volatility and perceived development issues. This polarization underscores the ongoing discussion regarding KAS's innovative technical claims versus its market performance and adoption challenges.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing dynamic trading as the broader Nasdaq market navigates shifting sentiment around Federal Reserve rate cut expectations and easing geopolitical tensions. Community discussions reflect a mix of aggressive dip-buying on hopes for an amplified tech rally and caution regarding leveraged ETF decay amidst mixed corporate earnings. While some express concern about volatility, a significant portion of the community remains bullish, anticipating continued upside momentum.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health (HROW) is trending as its VEVYE dry eye treatment gains significant market traction following a major PBM's decision to make it a preferred product, replacing a key competitor. The community is buzzing with optimism about VEVYE's accelerating sales momentum and eagerly anticipates upcoming product launches, fueling speculation around a potential short squeeze and the stock's long-term value in the ophthalmic sector.

ETHZilla Corp. is a technology company in the decentralized finance (DeFi) industry, which intends to connect financial institutions, businesses, and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It continues to maintain the deployment and development of its biotech and gaming operations. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZilla Corporation is actively trending following corporate moves to cancel executive stock awards and redeem convertible debt, actions that are generating buzz about a tighter share float and reduced overhang. While many anticipate a short squeeze and value appreciation tied to its Ethereum holdings and new real-world asset tokenization strategy, a significant portion of the community expresses concern over management's past decisions and potential dilution, leading to a polarized outlook on the stock's direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


kuwinnetco

KUWIN net co